Dialysis upgrade: can adding a filter remove more toxins?

NCT ID NCT05639010

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a special filter (hemoperfusion) to regular dialysis can better remove waste products like beta-2 microglobulin, parathyroid hormone, and C-reactive protein from the blood. About 410 adults with end-stage kidney disease on maintenance dialysis will be randomly assigned to standard dialysis or dialysis plus the extra filter once a week. The goal is to see if the combination improves toxin clearance, which could help manage the disease better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
hemoperfusion device (KHA80) combined with hemodialysis
What this could lead to
If it works, this could lead to a better way to remove harmful substances from the blood in people on dialysis, potentially improving their health and quality of life.
What could go wrong
This is a mid-stage trial testing a device, not a new drug. The benefits may be modest, and the results might not apply to all dialysis patients. Risks include possible side effects from the added procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Changhai Hospital

    Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.